Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed
Trial Parameters
Brief Summary
This is a prospective, single-center, open, single-arm clinical study to observe and evaluate the efficacy and safety of Fruquintinib and Adebrelimab combined with paclitaxel/albumin paclitaxel for second-line treatment of advanced gastric cancer.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years old. 2. The ECOG score is 0-1 and does not deteriorate within 7 days. 3. Patients with histologically confirmed, metastatic, or unresectable locally advanced gastric cancer or GEJ adenocarcinoma. 4. Previously received one systemic chemotherapy regimen for this cancer and progressed; Or have received adjuvant chemotherapy, but have disease progression or recurrence within 6 months after the end of treatment. 5. First-line exposure to PD-1 antibodies and first-line treatment of PFS greater than 9 months. 6. Measurable lesions that meet RECIST 1.1 criteria. 7. Have adequate organ and bone marrow function, laboratory tests meet the following requirements: 1. HGB≥90g/L; 2. NEUT≥1.5×10\^9/L; 3. PLT ≥80×10\^9/L; 4. TBIL≤1.5 times upper limit of normal value (ULN); 5. ALT and AST≤2.5 x ULN; In liver metastasis, ALT and AST≤5×ULN; 6. Endogenous creatinine clearance ≥50ml/min (Cockcroft-Gault formula); 7. Urinary protein \< (++), or 24-hour urinary protei